ReviewGene therapy2008
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells.
Review in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 276 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
276 citing papers in PubMed, 2 syntheses or guidelines pooled it, 576 citations in OpenAlex.
- Strategies to enhance efficacy of SPION-labeled stem cell homing by magnetic attraction: a systemic review with meta-analysis.International journal of nanomedicine · 2019Pooled it
- Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.Stem cell research & therapy · 2018Pooled it
- Article
- Multi-armored mesenchymal stem cells potentiate antitumor immunity to combat ovarian cancer.Stem cell research & therapy · 2026Article
- Mesenchymal stem cells promote cisplatin resistance in non-small cell lung cancer through IL-6/MEK-ERK/macrophages axis: construction of prognostic signature and experimental investigation.Frontiers in pharmacology · 2026Article
- Human stem cells loaded with visible and near-infrared fluorescent core-shell polymeric nanoparticles and revealing tropism toward inflammatory stimuli: in vitro evaluation.Stem cell research & therapy · 2025Article
- Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution.Journal of hematology & oncology · 2025Review
- Multi-function of adipose-derived stem cells on gut disorder: from bench to bedside.Stem cell research & therapy · 2025Review
- Antitumoral Efficacy of AuNRs-Laden ECFCs In Vitro and In Vivo: Decoding the Heat and Rays Combo Treatment in Breast Cancer and Melanoma Cells.Advanced healthcare materials · 2025Article
- Gene and Cell Therapy for Sarcomas: A Review.Cancers · 2025Review
- Engineered mesenchymal stem/stromal cells against cancer.Cell death & disease · 2025Review
- Immune gene features and prognosis in colorectal cancer: insights from ssGSEA typing.Discover oncology · 2025Article
- Platelet-rich plasma as a promising bioscaffold for enhancing peripheral nerve regeneration: An experimental study in a rat sciatic nerve model.Journal of biological methods · 2025Article
- Recent Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Engineering Strategies for Precise Strike Therapy against Tumor.Biomaterials research · 2025Review
- Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment.Current topics in medicinal chemistry · 2025Review
- Mesenchymal stromal cells as cancer promoters.Oncogene · 2024Review
- How to enhance MSCs therapeutic properties? An insight on potentiation methods.Stem cell research & therapy · 2024Review
- MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle.Cell biology and toxicology · 2024Review
- Syngeneic mesenchymal stem cells loaded with telomerase-dependent oncolytic adenoviruses enhance anti-metastatic efficacy.Stem cells translational medicine · 2024Article
- Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions.Signal transduction and targeted therapy · 2024Review
216 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Mesenchymal stem cells (MSC) exhibit tropism for sites of tissue damage as well as the tumor microenvironment. Many of the same inflammatory mediators that are secreted by wounds are found in the tumor microenvironment and are thought to be involved in attracting MSC to these sites. Cell migration is dependent on a multitude of signals ranging from growth factors to chemokines secreted by injured cells and/or respondent immune cells. MSC are likely to have chemotactic properties similar to other immune cells that respond to injury and sites of inflammation. Thus, the well-described model of leukocyte migration can serve as a reasonable example to facilitate the identification of factors involved in MSC migration. Understanding the factors involved in regulating MSC migration to tumors is essential to ultimately develop novel clinical strategies aimed at using MSC as vehicles to deliver antitumor proteins or suppress MSC migration to reduce tumor growth. For example, radiation enhances inflammatory signaling in the tumor microenvironment and may be used to potentiate site-specific MSC migration. Alternatively, restricting the migration of the MSC to the tumor microenvironment may prevent competent tumor-stroma formation, thereby hindering the growth of the tumor. In this review, we will discuss the role of inflammatory signaling in attracting MSC to tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.